Brief: Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
23/09/2024 14:20
Sept 23 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA™ BIOLOGICS ACHIEVES TARGET PATIENT ENROLLMENT IN
THE
VIRAGE PHASE 2B TRIAL OF VCN-01 WITH GEMCITABINE/NAB-PACLITAXEL
FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER
Source text for Eikon: ID:nGNX7gSht4
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025